Systemic lupus erythematosus biomarkers: the challenging quest
SLE, a multisystem heterogeneous disease, is characterized by production of antibodies to
cellular components, with activation of both the innate and the adaptive immune system …
cellular components, with activation of both the innate and the adaptive immune system …
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
BH Rovin, YKO Teng, EM Ginzler, C Arriens, DJ Caster… - The Lancet, 2021 - thelancet.com
Background Voclosporin, a novel calcineurin inhibitor approved for the treatment of adults
with lupus nephritis, improved complete renal response rates in patients with lupus nephritis …
with lupus nephritis, improved complete renal response rates in patients with lupus nephritis …
Safety and efficacy of long‐term Voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial
A Saxena, EM Ginzler, K Gibson… - Arthritis & …, 2023 - Wiley Online Library
Objective AURORA 2 evaluated the long‐term safety, tolerability, and efficacy of voclosporin
compared to placebo in patients with lupus nephritis (LN) receiving an additional two years …
compared to placebo in patients with lupus nephritis (LN) receiving an additional two years …
[HTML][HTML] Placebo-controlled randomized clinical trial of fish oil's impact on fatigue, quality of life, and disease activity in systemic lupus erythematosus
Introduction A recent metabolomic screen of sera from patients with Systemic Lupus
Erythematosus (SLE) found reduction of antioxidants and substrates for energy generation …
Erythematosus (SLE) found reduction of antioxidants and substrates for energy generation …
Heightened cleavage of Axl receptor tyrosine kinase by ADAM metalloproteases may contribute to disease pathogenesis in SLE
Systemic lupus erythematosus (SLE) is characterized by antibody-mediated chronic
inflammation in the kidney, lung, skin, and other organs to cause inflammation and damage …
inflammation in the kidney, lung, skin, and other organs to cause inflammation and damage …
[HTML][HTML] Adults with systemic lupus exhibit distinct molecular phenotypes in a cross-sectional study
JM Guthridge, R Lu, LTH Tran, C Arriens, T Aberle… - …, 2020 - thelancet.com
Background The clinical and pathologic diversity of systemic lupus erythematosus (SLE)
hinders diagnosis, management, and treatment development. This study addresses …
hinders diagnosis, management, and treatment development. This study addresses …
Update on the efficacy and safety profile of voclosporin: an integrated analysis of clinical trials in lupus nephritis
C Arriens, YKO Teng, EM Ginzler… - Arthritis Care & …, 2023 - Wiley Online Library
Objective This integrated analysis evaluates the efficacy and safety of voclosporin, a novel
calcineurin inhibitor, at 23.7 mg twice daily in combination with mycophenolate mofetil …
calcineurin inhibitor, at 23.7 mg twice daily in combination with mycophenolate mofetil …
Establishing surrogate kidney end points for lupus nephritis clinical trials: development and validation of a novel approach to predict future kidney outcomes
M Mackay, M Dall'Era, J Fishbein… - Arthritis & …, 2019 - Wiley Online Library
Objective End points currently used in lupus nephritis (LN) clinical trials lack uniformity and
questionably reflect long‐term kidney survival. This study was undertaken to identify short …
questionably reflect long‐term kidney survival. This study was undertaken to identify short …
Antibody-array-based proteomic screening of serum markers in systemic lupus erythematosus: a discovery study
A discovery study was carried out where serum samples from 22 systemic lupus
erythematosus (SLE) patients and matched healthy controls were hybridized to antibody …
erythematosus (SLE) patients and matched healthy controls were hybridized to antibody …
Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype
S Slight-Webb, M Smith, A Bylinska, S Macwana… - Journal of Allergy and …, 2020 - Elsevier
Background Autoimmune diseases comprise a spectrum of illnesses and are on the rise
worldwide. Although antinuclear antibodies (ANAs) are detected in many autoimmune …
worldwide. Although antinuclear antibodies (ANAs) are detected in many autoimmune …